ARBUTUS BIOPHARMA INC

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Liposomal siRNA in Subjects With High Cholesterol

Phase 1

Terminated

Conditions: Hypercholesterolemia

Interventions: Drug: PRO-040201
Drug: Placebo

First Posted Date: 2009-06-25

Last Posted Date: 2010-01-22

Lead Sponsor: Arbutus Biopharma Corporation

Target Recruit Count: 23

Registration Number: NCT00927459

Locations: 🇺🇸
Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy